11 results about "Acute renal failures" patented technology

To provide a composition for preventing, ameliorating or treating a disease caused by protein nitration comprising a peptide with terminal tyrosine as an effective component.SOLUTION: A peptide with terminal tyrosine has an excellent effect of inhibiting protein nitration and also an excellent effect of preventing, ameliorating or treating disease symptoms in chronic immobilization stress-induced depression / cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.SELECTED DRAWING: None

Disclosed are substituted indole compounds and compositions. The substituted indole compounds and compositions can be used for treating or preventing acute renal failure in a subject. The compounds and compositions can also be used for treating an infectious disease or cancer.

A method for ameliorating a disease caused by nitration of tyrosine in protein includes administering a composition comprising tyrosine or a salt thereof to a subject in need thereof. Tyrosine as effective component of the present invention not only can enhance the activity of glutamine synthetase having reduced activity and but also has an effect of restoring the amount (i.e., ratio) of glutamine and glutamic acid in brain and the amount of ammonia to normal level, an effect of enhancing the insulin sensitivity in a model of type 2 diabetes, an effect of suppressing the excitotoxicity and oxidative stress in a model of epileptic seizure, an effect of reducing cerebral infarction and enhancing the activity of GS in a model of brain stroke, an effect of eliminating the nitration of tyrosine using human recombinant MnSOD, and an effect for acute renal failure and hyperammonemia.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein moiety A, R1, and R2 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia- reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism- related disease and genetic disorder of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The peptide with tyrosine at the terminal has an excellent effect of inhibiting protein nitration; the composition has an excellent effect of preventing, improving or treating disease symptoms in a chronic body-bound stress depression / cognitive disorder inducing model, an Alzheimer disease dementia model, an epileptic seizure model, a cerebral apoplexy model, a type 2 diabetes mellitus model, an acute renal failure model or a hyperammonemia model.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, (I) wherein cycle A, R1, R2, and R3 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, R3, and R4 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, and iron metabolism-related disease. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament.

The invention belongs to the technical field of medical artificial intelligence, and discloses a neural network model for predicting neonatal acute renal failure based on urine volume time sequence data, and the model comprises a mixed feature extraction module which is configured to extract urine volume time sequence features through a multi-time window mechanism, fuse basic information of a patient to form a multi-dimensional feature matrix, and store the multi-dimensional feature matrix; the basic information comprises gestational age, birth weight and Apgar score; the patient feature fusion module is configured to standardize the basic information of the patient and then splice the basic information with the urine volume time sequence feature matrix; the multi-scale classification network is configured to perform cross-branch feature weighted fusion through an attention mechanism based on parallel convolutional neural network branches and full-connection network branches; and the loss function optimization module is configured to dynamically adjust the sample weight by adopting a loss function and a sample scheduling strategy. By adopting the method and the device, the timeliness, the accuracy and the reliability of generalization ability of the AKI prediction of the newborn can be ensured, and early warning and personalized medical treatment are realized.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, and R3 have the same meaning as that defined in the claims and the description, wherein said compound is used as a medicament for oral administration. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as medicament for oral administration in methods of prevention and / or treatment of such diseases.

As a compound that can be used as a therapeutic or preventative agent for diseases involving TRPC6, such as nephrotic syndrome, membranous nephropathy, acute renal failure, sepsis, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumors, and muscular dystrophy, a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided (where Ar... 1 Ar 2 X 1 ~X 3 R 1 R 3 R 7 R 8 and L 1 L 2 (As defined in the instruction manual).